Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
Antipsychotic discontinuation rates are a powerful indicator of medication effectiveness in schizophrenia . We examined antipsychotic discontinuation in the Schizophrenia Outpatient Health Outcomes ( SOHO ) study , a 3-year prospect i ve , observational study in out patients with schizophrenia in 10 European countries . Patients ( n=7728 ) who started antipsychotic monotherapy were analyzed .  Medication discontinuation for any cause ranged from 34 % and 36 % for clozapine and olanzapine , respectively , to 66 % for quetiapine . Compared to olanzapine , the risk of treatment discontinuation before 36 months was significantly higher for quetiapine , risperidone , amisulpride , and typical antipsychotics ( oral and depot ) , but similar for clozapine .  Longer medication maintenance was associated with being socially active and having a longer time since first treatment contact for schizophrenia , whereas higher symptom severity , treatment with mood stabilizers , substance abuse , having hostile behaviour were associated with lower medication maintenance . Antipsychotic maintenance in SOHO was higher than the results of previous r and omized studies
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .